Search clinical trials for: BMS-986120

Total 3169 results

Biogen

Terminated

Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

Supranuclear Palsy, Progressive

United States, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Austria, Canada, Germany, Japan, Australia, Greece
Columbia University
Bristol-Myers Squibb; Ferring Pharmaceuticals

Active, not recruiting

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P)

Prostate Cancer

United States
Bristol-Myers Squibb

Completed

A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants

Healthy Volunteers

United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Healthy Participants

Germany
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 in Healthy Participants

Healthy

Belgium
Biogen

Completed

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy (CN002-003)

Progressive Supranuclear Palsy

United States
Ronald Levy
Bristol-Myers Squibb

Completed

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid Neoplasm

United States
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Gastric Adenocarcinoma | Esophagogastric Cancer | Gastroesophageal Junction Adenocarcinoma | Esophagus Cancer | Gastroesophageal Junction Squamous Cell Carcinoma

United States
Bristol-Myers Squibb

Completed

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020

Immunosuppression For Disease
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

Healthy

United States
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

Acute Coronary Syndrome

United States, Taiwan, Korea, Republic of, Italy, South Africa, Belgium, Argentina, Israel, Malaysia, Romania, Serbia, China, Australia, Netherlands, United Kingdom, Denmark, Czechia, Hungary, Japan, France, Canada, Bulgaria, Spain, T... and more
Janssen Research & Development, LLC
Bristol Myers Squibb Company (BMS)

Recruiting

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK)

Ischemic Stroke; Ischemic Attack, Transient

Italy, United States, Hong Kong, Japan, Taiwan, South Africa, Korea, Republic of, Israel, United Kingdom, Argentina, Belgium, New Zealand, Canada, Germany, Czechia, Denmark, Mexico, Croatia, France, Australia, Brazil, China, Hungary, ... and more
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Myelofibrosis

Italy, Spain, United States, Australia, France, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Romania
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors (RELATIVITY 059)

Advanced Solid Tumors

China
Thomas Jefferson University
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Larynx | Squamous Cell Carcinoma | Lip | Oral Cavity Squamous Cell Carcinoma | Pharynx

United States
M.D. Anderson Cancer Center

Active, not recruiting

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Carcinoma in the Liver | Metastatic Carcinoma in the Lung | Metastatic Malignant Neoplasm in the Thoracic Cavity

United States
Bristol-Myers Squibb

Completed

A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Melanoma | Skin Cancer

United States, Canada, Netherlands, Spain, Australia, Italy, Japan, Germany, Ireland, United Kingdom, Czechia, Switzerland, Poland, France, Greece, New Zealand
Bristol-Myers Squibb

Completed

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Psoriasis

United States, Germany, Australia, Canada, Japan, Latvia, Mexico, Poland
Bristol-Myers Squibb

Completed

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

Healthy Adult

United States
Bristol-Myers Squibb

Completed

Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants

Thrombosis

United States
Bristol-Myers Squibb

Terminated

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Healthy Adult Volunteers

United States
M.D. Anderson Cancer Center

Active, not recruiting

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Advanced Lung Carcinoma | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Malignant... and other conditions

United States
Bristol-Myers Squibb

Completed

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

Lupus

United Kingdom
Ronald Levy
National Cancer Institute (NCI)

Active, not recruiting

TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | B-Cell Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
University Medical Center Groningen

Completed

PD-L1 PET Imaging in Melanoma Patients

Melanoma

Netherlands
Bristol-Myers Squibb

Active, not recruiting

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy (HORIZON-HCM)

Cardiomyopathy, Hypertrophic Obstructive

Japan
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Terminated

Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis

Healthy Volunteers | Ulcerative Colitis

Australia, Georgia, Moldova, Republic of
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

Arthritis

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM)

Cardiomyopathy, Hypertrophic

Spain, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Israel, Japan, Netherlands, Norway, Poland, Portugal, United Kingdom, United States, Australia, China, Czechia, India, Italy, Korea, Republic of
LianBio LLC

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Obstructive Hypertrophic Cardiomyopathy

China
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Broad Solid Tumor

United States, Argentina, Australia, Canada, Chile, Japan, Romania, Singapore
Northwestern University
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma

United States
Bristol-Myers Squibb

Completed

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Advanced Cancer

United States, Israel, Australia, Austria, Canada, Italy
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

Ischemic Stroke

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism Study in Healthy Male Participants

Cancer

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

Malignant Solid Tumor

United States, France, Italy, Australia, Canada, Germany, Netherlands
Bristol-Myers Squibb

Terminated

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Hepatocellular Carcinoma

Canada, Singapore, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

Healthy Volunteers

United Kingdom
Bristol-Myers Squibb

Completed

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Italy, United States, Argentina, Belgium, Germany, Israel, Poland, Spain, Turkey, Australia, Chile, France
Bristol-Myers Squibb

Completed

An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Advanced Cancer

United States, Belgium, Canada
Bristol-Myers Squibb

Active, not recruiting

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Advanced Cancer

France, United States, Spain, Australia, Italy, Switzerland, United Kingdom

Search clinical trials for: BMS-986120

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations